A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma
A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): SADAL: Selinexor and Dexamethasone in Aggressive Lymphoma

Read more
A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study
A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

Read more
A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma
A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

A Clinical Study to Demonstrate Safety and Efficacy of E7777 (Denileukin Diftitox) in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Read more
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

A Phase 2 Single-Arm, Open-Label Study of Brentuximab Vedotin as Front-Line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Read more